# Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

> **NCT05248633** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 220 (estimated)

## Conditions studied

- Solitary Plasmacytoma

## Interventions

- **RADIATION:** radiotherapy
- **DRUG:** Bortezomib Injection
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT05248633
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-21
- **Primary completion:** 2026-04
- **Final completion:** 2026-10
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05248633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05248633, "Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05248633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*